fevipiprant   Click here for help

GtoPdb Ligand ID: 8995

Synonyms: NVP-QAW039 | QAW039
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Fevipiprant is an orally available, selective antagonist of the prostanoid DP2 receptor (CRTh2) with anti-inflammatory action [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 97.64
Molecular weight 426.09
XLogP 3.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(=O)Cc1c(C)n(c2c1cccn2)Cc1ccc(cc1C(F)(F)F)S(=O)(=O)C
Isomeric SMILES OC(=O)Cc1c(C)n(c2c1cccn2)Cc1ccc(cc1C(F)(F)F)S(=O)(=O)C
InChI InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
Immunopharmacology Comments
Fevipiprant is being investigated primarily as an anti-asthmatic agent. If successful in clinical trial, fevipiprant would be the first oral anti-asthmatic to reach the market and could revolutionise treatment for patients suffering from moderate or severe corticosteroid-resistant asthma.
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Phase 3 clinical candidate for Asthma.